RxDoctor Payments Data

Hossein Ansari, MD

Neurology · San Diego, CANPI 1578774949

Payments from drug & device makers

$460,171in general payments, 2019–2025

Across 1,007 payments — averaging $456.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$79K
  • AbbVie$62K
  • Impel Pharmaceuticals Inc.$59K
  • Lilly USA, LLC$51K
  • Biohaven Pharmaceuticals, Inc.$40K
  • Lundbeck LLC$40K
  • plus $128K from 34 others
$2,908in research payments, 2019–2025

Across 2 payments — averaging $1453.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$3K

What the payments were for

  • Consulting fees$79,06521%
  • Speaking & faculty fees$259,95569%
  • Grants$880%
  • Travel & lodging$17,2895%
  • Food & beverage$19,9645%
  • Education$2140%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$460,171 in reported general payments places this provider in the 90th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$181,129
Medicare patients
109
Services billed
20,427

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate85$150,376
UbrelvyUbrogepant41$60,406
Emgality PenGalcanezumab-Gnlm44$31,340
Aimovig AutoinjectorErenumab-Aooe22$26,313
QuliptaAtogepant20$20,919
ReyvowLasmiditan Succinate14$10,544
Celecoxib24$4,062
Eszopiclone11$2,745
Oxcarbazepine34$1,587
Sumatriptan Succinate33$1,473
Almotriptan Malate13$1,211
Acetazolamide20$1,068
Gabapentin62$1,038
Naratriptan Hcl44$1,017
Lamotrigine37$771

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt$12,432$150,37685 claims
AbbVieUbrelvy, Qulipta$62,372$81,32561 claims
Lilly USA, LLCReyvow$51,436$10,54414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,996 neurology providers in California.

Other neurology in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →